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Abstract
Aim. Testosterone deﬁciency is having an increasing impact on men’s health because of global aging, higher levels of
obesity, diabetes and metabolic syndrome and adverse environmental factors such as stress xenoestrogens and anti-
androgens. The question addressed is to what extent the large body of evidence on the beneﬁts and safety of testosterone
therapy is applied in clinical practice.
Methods. Demographic data for men over the age of 50 from different regions of the world have been compared with the
number of men in that age group estimated from sales ﬁgures to be receiving testosterone treatment.
Results. On the basis of estimate that 20% of men over 50 in the general population of each region could be expected to have
testosterone deﬁciency symptoms, on average only these men (0.69%) in most European countries were receiving treatment.
Proportion was higher in the UK (1.00%) and Germany (1.89%), but lower in France (0.49%), Italy (0.51%) and Russia
(0.54%). Interestingly, Australia had higher ﬁgures (1.64%), in spite of tight state control measures on androgen use. The
USA has the highest treatment rate (7.96%) and this is increasing rapidly.
If the basis for the diagnosis was the more conventional combination of symptoms plus biochemical evidence of low total
and free testosterone levels, androgen deﬁciency would be expected in at least 5% of men over 50, and percentage treatment
rates therefore four times higher. However, even on that basis, only in the USA do these exceed 10%.
Conclusions. International action is urgently needed to raise awareness in the medical profession in the various countries of
these remarkably low levels of testosterone treatment. Improvement in this requires education and motivation of doctors and
those regulating the healthcare systems. A public awareness campaign is needed to educate men about the symptoms of
testosterone deﬁciency and its impact on their health.
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Introduction
Global Warming – ‘February 2nd 2007 will be
remembered as the day when global thinking about
climate change moved from debate to action’ (Achim
Steiner Executive Director UN Environment Pro-
gram).
ThisMilleniumhasseenrapidlygrowing awareness of
the important role that testosterone plays in main-
taining men’s health and quality of later life.
Testosterone deﬁciency is now recognised as a very
real and increasing problem for several reasons.
Global aging is occurring rapidly, particularly in
both developed and developing countries, but an
increased life expectancy is not unfortunately being
accompanied by greater health expectancy – the gap is
widening. With age, testosterone levels fall, and there
is greater resistance to its action, partly because of
rising Sex Hormone Binding Globulin (SHBG) levels
causing a more marked drop in bioavailable and free
testosterone (FT) [1]. This reduction in testosterone
is made worse by illness and the drugs used to treat it,
especially in diabetes and metabolic syndrome, both
of which are increasingly exponentially. There is some
recent evidence that testosterone levels are falling
generally in men, both as seen in cohorts of the
population in Denmark [2] and in the USA [3], and
this is attributed to both lifestyle and environmental
factors. Included in the environmental causes are
likely to be the increasing effects of xenoestrogens and
anti-androgens, which in younger men appear also to
be having a potentially serious effect on reproductive
health [4].
Not only is the quality of a man’s life greatly
reduced by the characteristic symptoms of testoster-
one deﬁciency, which include loss of energy and
libido, erectile dysfunction, irritability, joint pains and
stiffness, memory impairment, irritability and depres-
sion, but there is well documented associated
morbidity and mortality in relation to a wide range
of serious conditions. There are many epidemiologi-
cal, theoretical and therapeutic studies linking low
androgen levels in men with cardiovascular disease
[5,6], metabolic syndrome [7,8], diabetes [9,10],
osteoporosis [11,12], frailty [13,14] and Alzheimer’s
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now well recognised associations, life expectancy is
also decreased by androgen deﬁciency (AD) [18,19],
and may partially explain the greater longevity of
women. This is emphasised by Wu et al. in the
European Male Aging Study [20], which shows the
complex multiple alterations in the hypothalamo –
pituitary – testicular axis function associated with
progressive age-related testicular impairment as well
as speciﬁc risk factors, and emphasisesthe importance
of maintaining testosterone levels in aging men.
Like global warming, awareness of the effects of
testosteronedeﬁciencyisalsoincreasingasthegeneral
public surf the oceans of information available on the
internet, but still the condition remains largely
unrecognised and untreated. The symptoms of
‘Testosterone Deﬁciency Syndrome’ (TDS) as it has
come to be called in preference to andropause or late-
onset hypogonadism, were considered relatively rare
in the 1940’s when it was recognised as the ‘male
climacteric’, but are now frequently seen in middle-
aged and older men.
Prevalence of TDS
The prevalence of TDS in different countries is a
matter of intense academic debate. Estimates of its
frequency in the general community vary as widely
as between 0.5% [21] and on a symptomatic basis
in men over 50, nearly 50% [3], a 100-fold
difference.
The answer depends on the population of men
studied, their age, and whether symptoms alone are
considered diagnostic or additional laboratory criter-
ia such as testosterone level are required. These polar
views both need to be considered, because the
biochemical criteria can be questioned on the
grounds of validity of androgen assays [22], and
their signiﬁcance in the light of the concept of
androgen resistance, akin to that seen with insulin in
Type 2 diabetes mellitus [1].
Large-scale epidemiological studies such as the
Boston Area Community Health (BACH) Survey [3]
have shown that while 37.7% of men over the age
of 50 reported symptoms of AD, only 15% had low
total testosterone (TT), 9.9% low FT and 8.4% both.
This left 15% with low levels of TT or FT, and no
symptoms. The very poor overlap of symptoms and
biochemistry seen in most clearly in Venn diagrams
resulting from such studies raises the question of
who should be given access to a therapeutic trial of
testosterone, the patients with symptoms, even if they
lack a biochemical passport or only those with both?
Using the best validated and most widely studied
questionnaire, the Aging Male Symptoms (AMS)
scale [23,24], Heinemann found a prevalence of
moderate and severe symptoms of testosterone
deﬁciency in around 20% for European men over
50 [25] from an aggregate of studies in Germany,
UK, France, Spain, Portugal, Italy and Sweden. This
international comparison, using the questionnaire
meticulously translated into the various languages
[26] showed closely similar correlations between the
total scores and sub-scales, both in ‘community
populations’ in all countries studied, and in patients
in urology clinics in Germany and Austria [27].
Like all questionnaires designed to detect symp-
toms of AD, the AMS scale shows little or no
correlation with either TT or other endocrine
measures such as calculated free testosterone
(CFT) [28]. Importantly, it is however an efﬁcient
means of predicting and measuring clinical response
to symptoms of testosterone deﬁciency, which could
be taken as a true measure of its clinical validity. Of
1670 urology clinic patients treated with Testogel for
3 months, 73% had moderate (35%) or severe (38%)
symptoms before, and only 22% afterwards, (20%
moderate and 2% severe), a much more normal
picture [29]. This improvement was not related to
age, BMI or testosterone levels. Similar results were
obtained in a study of patients in another German
urology clinic given testosterone enanthate injections
[28], showing the symptomatic response is not
dependant on testosterone preparation providing
the dosage is adequate.
All self-reported questionnaires have good sensi-
tivity, but low speciﬁcity in relation to androgen
values. The St. Louis Androgen Deﬁciency in the
Aging Male (ADAM) questionnaire [30] has been
extensively used, but some of the claimed correlation
with testosterone levels are likely to be age-related
[31]. Although the ANDROTEST questionnaire
gave higher speciﬁcity than the ADAM in relation
to both TT and FT [32], clinical experience with it is
limited as it has only been used by its originating
group in the 2 years since it was published.
Because it is fully recognised that the current
consensus view of the major societies in the ﬁeld
require biochemical conﬁrmation of the diagnosis,
ﬁgures for those with additional biochemical evi-
dence, as well as those with symptoms alone, will be
given later in this article.
Prevalence of testosterone treatment
It is of importance to compare the number of men
over 50 in various countries, for which accurate
ﬁgures are available from ofﬁcial demographic
surveys such as Eurostats, US Census Bureau,
Health Statistics from the Americas 2006 (Pan
American Health Organisation) and Australian
Bureau of Statistics, with testosterone usage in those
regions (Tables I and II).
The number of men on testosterone treatment is
difﬁcult to estimate accurately because moving
annual turnover ﬁgures from different governmental
and commercial agencies often give only the mone-
tary value and number of packs of testosterone sold.
Each pack may provide a variable duration of
treatment, depending on the preparation and dosage.
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testosterone esters or testosterone enanthate last on
average 3 weeks, this means that 18 single dose packs
are dispensed for each patient yearly. Similarly, some
oral preparations such as testosterone undecanoate
are dispensed in packs lasting for either 2 weeks or a
month, as are testosterone gels and patches. Long-
acting testosterone undecanoate injections last 3
months, and testosterone implants last about 1
month per 200 mg pellet, assuming six pellets are
implanted every 6 months. Given ﬁgures for the
number of packs of each preparation prescribed per
year, as are available for the UK, Russia and
Australia, it is possible to obtain a fair approximation
for the number of patients receiving testosterone
treatment in each country. These ﬁgures are only
estimates, and may well have to be revised up or
down as more accurate data becomes available from
international studies.
Unfortunately, there is also no indication of the
proportion of treated patients who are receiving
treatment for conditions other than adult onset
testosterone deﬁciency e.g. Klinefelter’s Syndrome
estimated at 0.2%, but undiagnosed in many cases
[33], undescended testis (0.2%) [34], which
also remains undiagnosed or untreated in over 50%
of cases. Though excluded where possible in
these analyses, prescriptions for women have been
estimated at 0.05% (IMS ﬁgures), and are probably
increasing especially in the US where surprisingly, as
the toxic methyl testosterone, they have long been a
component of hormone replacement regimes.
Table II shows the number of men over 50 years
who are estimated to have symptoms of testosterone
deﬁciency compared with the number of men
receiving treatment, based on one of two assump-
tions. Firstly, if the diagnosis deﬁciency is made on
presence of symptoms alone, for example a moderate
to severe score on the AMS scale, based on the
existing ﬁgures it would be reasonable to assume a
prevalence of 20% in men over the age of 50.
Alternatively, if in spite of the low degree of
overlap, both symptomatic and biochemical evidence
in the form of low TT and FT is required to conﬁrm
the diagnosis, only about 5% could be expected to
have AD [3], which quadruples the percentage of
cases treated in each region.
With either scenario, the number of cases
treated includes half the cases of Klinefelter’s
Syndrome, i.e. 0.1%, and half of the undescended
testes, i.e. 0.1%. The estimates are based on 2006–
2007 ﬁgures from Intercontinental Medical Statis-
tics. (IMS), Bayer-Schering Russia and Medicare
Australia.
USA
In a few countries, notably the USA which now
represents about 90% of the market for testosterone
products, the treatment is becoming more widely
used, but in most usage is static and minimal, as
pharmaceutical companies trying to introduce new
preparations elsewhere have found to their cost. The
rapid expansion in the USA is largely because of
rapidly growing public awareness and enthusiasm for
testosterone treatment fostered by the internet,
together with safer and more convenient products,
as well as easier access though private physicians
rather than in a state-funded system.
There the market for testosterone therapies has
increased from US $49 million to almost $400
million between 1997 and 2003, with the majority
of prescribing being for men 40 years and older [35].
It has been reported that the average annual increase
Table I. Numbers of men in millions at risk of TDS in various age
categories, estimates being made around 2006.
Region Age 50–64 Age 65–79 Age 80þ
Whole EU 42.53 29.61 9.63
UK 4.99 3.26 1.23
Ireland 0.33 0.17 0.04
Spain 3.44 3.25 1.23
Italy 5.23 4.17 1.46
France 5.32 3.45 1.36
Germany 6.48 5.21 1.58
America 25.14 11.76 3.82
Russia 10.60 4.90 1.50
Australia 1.72 0.94 0.27
Table II. Number of men over 50, and those expected to be androgen deﬁcient on the basis either of symptoms alone (20%), or with
symptoms and low TT and CFT (5%), compared with total number being treated in each region. Estimates are made for around 2006.
Region
Men aged
450 (Millions)
TDS
symptoms
(Millions)
Total
number
treated
Symptoms
treated (%)
Sympt.þ
biochem.
(Millions)
Symptomsþ
biochem
treated (%)
Whole EU 81.77 16.35 113,000 0.69 4.09 2.76
UK 9.48 1.90 19,000 1.00 0.47 4.00
Ireland 0.54 0.11 1,000 1.10 0.27 4.40
Spain 7.92 1.58 12,000 0.76 0.40 3.04
Italy 10.86 2.17 11,000 0.51 0.54 2.03
France 10.13 2.03 10,000 0.49 0.51 1.97
Germany 13.27 2.65 50,000 1.89 0.66 7.55
America 40.72 8.14 648,000 7.96 2.04 31.84
Russia 17.00 3.40 18,400 0.54 0.85 2.16
Australia 2.93 0.59 9,100 1.54 0.15 6.17
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treatment had reached 29% by 2002 [36], so that
total sales were likely to have gone over the 1 Billion
$US mark by 2007.
However, the same detailed and authoritative
‘Testosterone and Aging’ report from the US Board
of Health Sciences Policy in 2004 [36] using US
census data estimated that in 2002, 1.14% of 46–65
year old males were using testosterone products
(58% of total retail patient count), compared with
0.56% of men over 65 (13% of total retail patient
count), and that this was increasing by about 20%
annually in both groups. Linear extrapolation, which
again may well be an underestimate especially in view
of the rapid increase in illicit Internet sales, gives a
frequency of usage of 31.8% of biochemically
conﬁrmed cases in 2006.
Allowing for 20% annual increase in usage, and
higher frequency of AD in older age groups, these
ﬁgures are supported by a recent study in the BACH
Survey, showing that of the 5.5% of men in the age
range 30–79 years in 2002 who fulﬁlled their criteria
of AD, i.e. had symptoms of AD together with low
total and FT, only 12.2% were receiving testosterone
treatment [37]. The authors conclude that ‘a large
majority of men in our groups with AD were not
receiving treatment despite adequate access to care.
The reasons for this are unknown but could be
because of unrecognised AD or unwillingness to
prescribe testosterone therapy’. These are important
themes are taken up later in this article.
Europe
By contrast, according to ﬁgures for Europe and the
UK provided by IMS and British Pharmaceutical
Index (BPI Data), compared with demographic
ﬁgures from Eurostats, testosterone usage in Europe
is generally much lower, averaging 1% or less of men
with symptoms, except in Germany where it is better
recognised and more accepted. This is in spite of
recent statements by European authorities that
‘Measurements recorded to date suggest that
*12% of men aged 50–59 years, 19% of men aged
60–69 years, 28% of men aged 70–79 and even 49%
of men over 80 suffer from hypogonadism’ [38].
Also, the market in Europe is virtually static,
increasing by only 0.2% between 2007 and 2008.
Russia
In Russia, there is a rapid reduction in life expectancy
for men, which has now fallen to about 58 years
because of factors such as psychosocial stress and the
ravages of alcohol. This results in a rapid fall off in the
number of men over the age of 50, and a high pre-
valence of TDS in this group due to the same factors.
Analysis of the testosterone market in Russia
shows doubling of the money spent on all testoster-
one preparations between 2001 and 2007. Unfortu-
nately, this obscures an estimated halving of the
number of men receiving any testosterone treatment,
largely due to greatly reduced prescribing of the low
cost but toxic methyl testosterone which was given in
over 75% of cases at the beginning of the period, and
still over 50% in 2006. This emphasises the need for
economic but safe products such as creams and gels
which can be applied to the scrotal skin, the site of
maximal transdermal absorption and hence econom-
ic and convenient use (Table III).
Australia
A rising trend in testosterone prescribing which
started in the mid-1990s was suppressed by two
successive rafts of legislation [39]. Combining
Australian Bureau of Statistics ﬁgures for 2006 with
those of Medicare Australia for Pharmaceutical
Beneﬁt prescriptions for 2006, it is estimated that
*1.54% of the men over 50 likely to have TDS
symptoms were receiving testosterone treatment, and
of those with biochemically proven AD, just over 6%
were being treated.
Causes of failure to treat androgen deﬁciency
The diagnosis of androgen deﬁciency is missed because of
over-emphasis on laboratory data at the expense of
clinical data, especially symptomatology
Led by epidemiologists, there has been a rush to
devalue and then dismiss the well-established clinical
symptoms of testosterone deﬁciency. This is on the
grounds that there is very poor correlation between
these and laboratory data, and that any links between
the two, especially when starting with non-speciﬁc
questionnaires such as the ADAM, are age-related.
Table III. Absorption, theoretical and practical advantages, together with costs, of each preparation and their application at NHS prices (£),
giving a monthly total treatment cost, excluding medical costs of diagnosis and monitoring treatment. Theoretical and practical aspects of
each treatment are rated from *poor, **moderate, ***good, to ****excellent.
Testosterone preparation % Abs. Theory Practice Cost Appl. Total
Testosterone pellet implant 100 * ** 14 50 64
Injected T-esters (Sustenon) 100 * * 5 20 25
Injected T-undecanoate (Nebido) 100 ** *** 25 5 30
Oral T-undecanoate (Testocaps) 10 ** ** 36 0 36
T-Gel (Testogel, Tostran, Testim) 15 *** *** 33 0 33
Scrotal T (Andromen, Tostran) 70 **** **** 13 0 13
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elderly Swedish population where as with other
studies, only a weak association was found between
symptoms in the ADAM questionnaire and blood
testosterone concentrations. On this basis, Mckinlay
in an editorial in the same issue of the Menopause
Journal concluded that the idea of a ‘hormonal
syndrome’ should be ﬁnally declared dead and given
a ‘decent burial’ [41].
However, also in 2007, the same group published
the previously quoted article on ‘The prevalence of
symptomatic AD in men’ [3], in which they posed
the question ‘What are the clinical risks of missing
these asymptomatic men with low testosterone levels,
if any?’ Given that in the large majority of cases,
regardless of age and androgen levels, the symptoms
as measured by the carefully designed, quantiﬁable
and non-aged related AMS scale can be reversed
[29], perhaps the question could be viewed from
another angle. – What are the clinical risks of missing
symptomatic men with ‘normal’ testosterone levels?
It is suggested that given characteristic symptoma-
tology, particularly in the presence of medical
conditions known to be associated with TDS, setting
arbitrary cut-off points for TT or CFT above which
AD can be deﬁnitely excluded is both scientiﬁcally
and clinically unjustiﬁed. This contention is sup-
ported by the existing evidence on the inconsistencies
in sampling procedures, laboratory analyses and
uncertainties about the interpretation and signiﬁ-
cance of so-called ‘normal ranges’ of androgens [22].
These problems surrounding the laboratory-based
diagnosis of TDS are compounded by the evidence
that there can be both insufﬁcient production, and
variable degrees of resistance to the action of
androgens operating at several levels in the body
simultaneously. These factors become progressively
worse with aging, adverse life-style, other disease
processes, and a wide range of medications [1].
Unfounded concerns about the side-effects of treatment,
especially in relation to prostate cancer
In a world-wide study of the attitude of physicians to
treating testosterone deﬁciency, apart from uncer-
tainties over diagnosis, by far the commonest barrier
in every country was fear of inducing prostate cancer
(pCA) (60%) [42]. This was combined with un-
founded concerns over the possible adverse effect on
benign enlargement of the prostate [43], and also
lack of awareness of the important role of T in
erectile dysfunction [44,45]. It is suggested that
physicians need to be updated on all these points.
The particular, the current state of knowledge on
T and pCA is best summarised by the statement in
the article that ‘current literature does not provide
any evidence of a cause – effect relationship between
endogenous T or T treatment and pCA develop-
ment’. Further, the concerns about any such link
been declared to be ‘A modern myth’ by the
American urologist Morgentaler who goes as far as
to state ‘that there is not now – nor has there ever
been – a scientiﬁc basis for the belief that T causes
pCA to grow’[46].
The overly cautious attitude of many physicians is
to suggest awaiting the out-come of large-scale
randomised placebo controlled trials, even though
these are unlikely to be funded or completed in the
lifetimes of most men currently needing treatment.
Further delay on these grounds also seems unjusti-
ﬁed in the light of the many studies carried out before
all recently licensed products were released, as well
as extensive post marketing surveillance, together
with 70 years clinical experience of safe and effective
testosterone treatment.
Lack of awareness of the many serious general medical
conditions in which androgen deﬁciency plays a major
role [47]
As referenced above, AD has been linked epidemio-
logically and clinically to many of the commonest, most
severely debilitating and distressing afﬂictions of aging
men, including cardiovascular disease, metabolic syn-
drome, diabetes, osteoporosis and Alzheimer’s disease.
As well as its overall health beneﬁts, sexual health is
improved by increased libido, and testosterone is
increasingly recognised as a a d j u n c tt oP D E 5i n h i b i t o r s
in treating erectile dysfunction [45]. Finally, testoster-
one treatment can reduce the distressing and expensive
period of frailty and dependency at the of end life.
The argument that many of the symptoms will
remit if left untreated [48] does not take into account
the damage done by the above conditions to the
man’s general health and quality of life while waiting
for the spontaneous which might occur 10–15 years
later in 50% of cases.
Lack of training in safe and effective testosterone
treatment
Guidelines for this have now been provided by the
International Society for Andrology, the Interna-
tional Society for the Study of the Aging Male and
European Association of Andrology [43], as well as
the Endocrine Society in America [49], and are
remarkably uniform in their safety recommendations.
An on-line training course based on these guidelines
has recently been established by the Society for the
Study of AD, and for the ﬁrst time makes the
theoretical and practical information needed to
diagnose and treat AD available to physicians
anywhere in the world (www.andropause.org.uk).
Concerns about the cost of treatment and failure to
appreciate the true long-term costs of not treating this
condition
There is a lack of awareness of recent advances in
safe and economic forms of androgen treatment, and
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methyl testosterone e.g. in France and Russia [50].
This has tended to over-shadow the economic as well
as the medical burden of TDS in terms of both
morbidity and mortality [51].
The costs of testosterone treatment have not been
studied in any detail, but need to be part of any
convincing cost/beneﬁt analysis. Table III compares
the features and monthly costs of the most commonly
used testosterone preparations in the UK at NHS
prices. Absorption varies widely from the total
utilisation of implanted and injected forms, to the
poor and variable absorption of the oral preparations.
Theoretical advantages of each preparation have
been rated according to the degree to which the
preparation restores a steady and natural physiologi-
cal endocrine pattern, avoiding supraphysiological
peaks of testosterone, and suppression of LH and
FSH which can cause distressing testicular shrinkage.
Practical considerations include the need for 6
monthly implant appointments, twice monthly injec-
tions by a nurse in the case of the injected T-esters,
or twice daily dosage with oral treatments, and the
patient’s preference for the various forms of treat-
ment. Also, as in the case of pellet implants and
injected T-esters, the costs of the preparation may be
exceeded by those of its application by scarce medical
and nursing staff.
In well developed health-care systems such as that
in the USA, there is emphasis on the concept of
‘preventive care’ in limiting spiraling costs in this
major segment of the economy, though there is
considerable debate over which clinical interventions
actually save money [52]. These authors raise the key
point that ‘Findings that some cost-saving or highly
efﬁcient measures are underused would indicate that
current practice is inconsistent with the efﬁcient
delivery of health care’. Testosterone treatment can
provide short and long-term improvement in the
quality of life, and be of beneﬁt in many serious and
debilitating conditions, when carefully targeted it
could be considered a strong candidate for providing
cost-effective preventive medical care.
Conclusions
International action is urgently needed in making
these problems known to the medical profession in
each country, and overcoming the obstacles to
treatment by educating and motivating them and
those regulating the healthcare systems, as well as
encouraging the public to be aware of symptoms of
TDS and its importance.
The proposed sequence of events is ﬁrstly that
primary care physicians should be made aware that
AD is important, frequently occurring, easily diag-
nosed by questionnaires such as the AMS, and safe,
simple and economic to treat. Without this initial
stage, many patients with diagnostic symptoms will
continue to go unrecognised and untreated.
Secondly, specialists such as urologists, especially
those treating erectile dysfunction, andrologists,
endocrinologists seeing patients with diabetes and
metabolic syndrome, cardiologists, psychiatrists and
gerontologists should all be more aware of the need
to recognise and treat the condition.
Last but not least, by un-sensational but author-
itative TV programs and articles in the popular press,
we can educate the general public, increasing their
awareness of the symptoms and effects of testoster-
one deﬁciency, and the efﬁcacy of treatment. The
economic case that it could be an important part
of preventive medical care in aging men with
testosterone deﬁciency needs to be developed and
publicised.
Like climate change, it could be said that the time
has come when global thinking on the need to
diagnose and treat testosterone deﬁciency should
move from debate to action.
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